Second Time’s The Charm: Amylyx’s ALS Drug Wins US FDA Panel Nod

 
• By Sue Sutter
Yes and no
Amylyx flipped several votes from "no" to "yes" in its second visit to the advisory committee. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers